See into the future of the business of diabetes
Diabetic Investor has been a must-read resource for investors in the diabetes space for over 20 years. Our Special Report “The Convergence of Forces” gives you a comprehensive look at the trends that will shape the industry for years to come.
A blueprint to anyone bold enough
This is not your average report. No fluff. No bull. Just facts and actionable analysis from David Kliff, who has lived with Type 1 diabetes for over 20 years and is trusted by some of the most respected names in pharma, medtech and Wall Street.
While others are caught off-guard, you’ll be ready. Advanced technology, new therapy options, AI, digital health. With each transformation, those from the old way of doing things will be desperately trying to adapt.
Trusted for over 20 years
The Diabetic Investor brings a historical perspective that can’t be matched by other analysts, and it shows.
• We made the call to buy Dexcom when it was below $60
• We predicted the failure of Exubera when everyone else called it a blockbuster
• We were first to report BGM devices would be marketed as consumer devices – not medical devices